Clinical trial
A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin in the Treatment of Patients With Transplantation Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04624893 is registered in ClinicalTrials.gov with Jiangsu Cancer Institute & Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin in the Treatment of Patients With Transplantation Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Lead sponsor
- Jiangsu Cancer Institute & Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- December 12, 2019
- Completion date
- December 31, 2020
- Enrollment
- 35 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse large b-cell lymphoma (dlbcl)